Prophylaxis and High-Risk Groups
Palivizumab (say "pah-lih-VIH-zu-mahb") is a monoclonal antibody that reduces hospitalizations due to RSV infection among children at high-risk for severe disease. It is given in monthly intramuscular injections during the RSV season, which generally lasts from November through March in most locations in the United States.
American Academy of Pediatrics (AAP) Guidelines for Infants and Children at Risk for Severe Illness Due to RSV Infection
According to the AAP1, palivizumab prophylaxis may be considered for the following infants and children
- Infants born at 28 weeks' gestation or earlier during RSV season, whenever that occurs during the first 12 months of life
- Infants born at 29–32 weeks' gestation if they are younger than 6 months of age at the start of the RSV season
- Infants born at 32–35 weeks' gestation who are younger than 3 months of age at the start of the RSV season or who are born during RSV season if they have at least one of the following 2 risk factors: 1) infant attends child care; 2) infant has a sibling younger than 5 years of age
- Infants and children younger than 2 years with cyanotic or complicated congenital heart disease
- Infants and children younger than 2 years who have been treated for chronic lung disease within 6 months of the start of the RSV season.
- Infants born before 35 weeks of gestation who have either congenital abnormalities of the airway or neuromuscular disease that compromises handling of respiratory secretions
Consult the American Academy of Pediatrics Red Book (28th edition, 2009) for more specific and latest recommendations, including the length of prophylaxis.
Increasingly, RSV infection is recognized as an important cause of respiratory illness in high-risk adults and the elderly. High-risk adults include those with chronic heart disease, chronic lung disease, or compromised immune systems; the elderly include those 65 or older, particularly if they reside in a long-term care facility or participate in other senior day-care programs.
- American Academy of Pediatrics. Respiratory Syncytial Virus. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009.
Images and logos on this website which are trademarked/copyrighted or used with permission of the trademark/copyright or logo holder are not in the public domain. These images and logos have been licensed for or used with permission in the materials provided on this website. The materials in the form presented on this website may be used without seeking further permission. Any other use of trademarked/copyrighted images or logos requires permission from the trademark/copyright holder...more
This graphic notice means that you are leaving an HHS Web site. For more information, please see the Exit Notification and Disclaimer policy.
Respiratory Syncytial Virus (RSV)
CDC Featured Podcast
Dr. Eileen Schneider talks about a common cause of respiratory illness in young children.
Listen To This Podcast (4:22)
- Centers for Disease Control and Prevention
1600 Clifton Rd
Atlanta, GA 30333
TTY: (888) 232-6348